This review provided an overview of currently unlicensed treatments for the treatment of chronic cough, including those in development for patients with refractory chronic cough and cough in idiopathic pulmonary fibrosis. As part of the review, an overview of how cough treatments are evaluated was provided. The authors noted that “regulatory bodies require a thoroughly validated objective cough monitoring system using a CE marked/FDA 510 K registered device as the primary endpoint in regulatory studies to demonstrate a therapy reduces the frequency of coughing”, adding that “the VitaloJAK cough monitor has been most frequently used” in this setting.
- Author Smith JA
- Publication Lung
- Year 2023
- Device Type VitaloJAK
